Brightening Claim Compliance: EU Restricted List, NMPA Whitening Cosmetic Regulation

Overview #

Brightening is one of the most commercially loaded claims in skincare — and one of the most legally exposed. Before we talk actives or textures, the first thing we ask any brand partner is: where are you selling this? Because “brightening” in the EU, “whitening” in China, and “dark spot corrector” in the US are not the same regulatory conversation. They’re not even close. The restricted ingredient lists diverge, the claim substantiation requirements diverge, and the packaging language that’s perfectly legal in one market can trigger a product recall in another. We’ve seen it happen. This guide walks through how we interpret a brightening brief from the ground up — the formulation decisions, the trade-offs, the timelines, and where projects typically go sideways.

Reading the Brief: What We Actually Need to Know First #

When a brand partner sends us a brightening brief, the document usually says something like “clean, brightening serum, targets hyperpigmentation, suitable for sensitive skin, EU + US launch.” That brief contains at least four potential conflicts we have to resolve before we touch a beaker.

The first question we ask: is this a melanin-suppression product or a radiance product? They sound similar. They are not. Melanin suppression — inhibiting tyrosinase, blocking melanosome transfer — requires actives with real regulatory exposure. Radiance is largely optical: light-diffusing particles, mild exfoliation, hydration. The formulation path, the claim language, and the regulatory dossier are completely different. Most brand owners haven’t made this distinction when they brief us. We almost always push back on this before moving forward.

The second question: what’s the EU restricted list exposure? EU Cosmetics Regulation 1223/2009 Annex II and Annex III are where brightening projects get killed. Hydroquinone is prohibited in cosmetics in the EU. Kojic acid is currently under SCCS review — the SCCS Scientific Opinion from 2021 set a maximum of 1% in face creams and 0.7% in hand creams, but the regulatory status is still evolving. Mercury compounds are banned globally. If a brand comes to us with a brief that includes any of these, we flag it immediately. We don’t wait until the stability study is done.

For China specifically, the NMPA Cosmetic Regulation classifies whitening/freckle-removing products as special-use cosmetics, which means a separate registration pathway, additional safety assessment requirements, and a whitening active ingredient that must appear on the NMPA’s approved list. As of the 2021 Cosmetic Supervision and Administration Regulation (CSAR) implementation, this pathway takes 6–12 months longer than a general cosmetic registration. Brands planning a China launch need to know this on day one, not month six.

Formulation Decisions and the Numbers That Actually Matter #

Once we’ve aligned on market and claim scope, we get into the formulation architecture. This is where most of the real trade-offs live.

For a tyrosinase-inhibiting system, the workhorse actives we use most frequently are alpha-arbutin (1.0–2.0%), niacinamide (4.0–5.0%), tranexamic acid (2.0–3.0%), and ascorbic acid derivatives — typically ascorbyl glucoside at 2.0% or 3-O-ethyl ascorbic acid at 1.0–2.0%. These are all EU-compliant, NMPA-listed, and have reasonable stability profiles when formulated correctly. The combination matters more than any single active. We typically run a niacinamide + tranexamic acid base and layer in an ascorbyl derivative depending on the pH target.

pH is where most brightening formulas fail at scale. Ascorbic acid and its derivatives want to sit at pH 3.0–4.5 for stability. Niacinamide converts to nicotinic acid — causing flushing — below pH 4.0 and above pH 7.0, but performs best around pH 5.5–6.5. Tranexamic acid is relatively pH-tolerant. You cannot optimize all three simultaneously. In our lab, we typically land at pH 4.8–5.2 as the compromise zone for a combined system, accepting slightly suboptimal ascorbyl stability in exchange for niacinamide safety. We buffer with citrate-phosphate and run accelerated stability at 40°C/75% RH for 12 weeks minimum before we sign off on a formula.

One failure we’ve seen repeatedly: a brand requests 10% niacinamide because they’ve seen it in competitor products. At 10%, in a formula with any acidic brightening active, the niacinamide-to-nicotinic acid conversion accelerates significantly. We had one batch — 150kg production run — where the formula passed our 500g lab stability at 8 weeks but showed visible yellowing and a detectable niacin odor by week 10 at production scale. The heat generated during high-shear mixing at scale was enough to push the conversion. We now cap niacinamide at 5% in any formula with pH below 5.5, and we require a niacin conversion assay at week 4 of PCT for every brightening SKU.

Encapsulation is the other lever brands ask about constantly. Encapsulated retinol or encapsulated vitamin C sounds compelling in a marketing deck. The stability improvement is real — we’ve seen encapsulated ascorbic acid hold at >85% potency through 12 weeks at 40°C versus ~40% retention for unencapsulated in the same base. But encapsulation adds roughly 2.5–3× the raw material cost for the active fraction. For a serum with 2% encapsulated 3-O-ethyl ascorbic acid, that can add $0.60–$1.20 per unit at MOQ 3,000. Most indie brands can’t absorb that without repricing the product. We’re honest about this upfront. See our encapsulation technology documentation for the full cost-benefit breakdown by active type.

The Hard Truth About Whitening Claims in China #

The NMPA pathway for whitening cosmetics is not just a longer registration. It’s a fundamentally different evidentiary standard. You need human efficacy data — not just in vitro tyrosinase inhibition, not just consumer perception surveys. The NMPA requires clinical or consumer use studies with measurable colorimetric outcomes, typically using Mexameter or Chromameter readings, with a minimum study duration of 28 days and a statistically significant improvement in ITA° (Individual Typology Angle) or L* value.

We’ve run these studies with our CRO partners. One study we reference frequently for tranexamic acid at 3% in an emulsion base: double-blind, split-face, n=42, 12 weeks, showed a mean L improvement of 2.8 units on the treated side versus 0.6 units on placebo. That’s a real signal. It’s also the kind of data the NMPA wants to see in a dossier. What it doesn’t tell you is how that translates to consumer perception — and in our experience, a 2.8 L unit improvement is visible to a trained colorimetrist but not always to the consumer in a mirror. Managing that expectation gap is part of our job when we brief brand partners on claim language.

The approved whitening actives list under NMPA includes nicotinamide (niacinamide), ascorbic acid and several derivatives, alpha-arbutin, kojic acid, and a handful of botanical extracts. Hydroquinone is not on the approved list for cosmetics. If a brand wants to use an active that isn’t on the list, they’re looking at a new ingredient notification process that adds 12–18 months and significant cost. We steer brands away from this unless they have a very specific reason and a very patient timeline.

One thing we’ve noticed in the market: brands launching in China often over-engineer the whitening active concentration because they assume higher = better claim support. In practice, the NMPA cares more about the study design and the colorimetric data than the concentration on the formula sheet. We’ve seen 2% alpha-arbutin with a solid clinical dossier sail through registration while a 4% formula with weak study design got flagged for additional data. Concentration is not the shortcut brands think it is.

Premium vs. Mass-Market Specs: Where the Real Differences Are #

This is a question we get at almost every kickoff. The honest answer is that the active ingredient list often isn’t where premium and mass-market diverge most. It’s the delivery system, the sensory profile, and the packaging.

The airless pump question comes up constantly. For any formula with ascorbyl actives, we recommend airless packaging — oxidation from repeated air exposure degrades vitamin C derivatives faster than almost any other stability variable. Airless pump adds $0.40–$0.80 per unit depending on volume and supplier. At MOQ 1,000, that’s a $400–$800 cost increase on packaging alone. Most indie brands at early stage can’t absorb that without crossing a retail price threshold that changes their competitive positioning. We’ve had brands go back to UV-protective glass with a disc pump as a compromise. It’s not a perfect solution.

For mass-market, the niacinamide + alpha-arbutin combination at the concentrations above is genuinely effective and genuinely cost-efficient. We’re not dismissive of it. The clinical evidence for niacinamide at 4–5% on hyperpigmentation is solid — multiple studies, consistent results. The issue is that every competitor is using the same combination, so differentiation has to come from texture, sensory, or brand story rather than the formula itself.

See our brightening and whitening formulation resource library for full active ingredient profiles and stability benchmarks.

Development Timeline: What Realistic Looks Like #

We get asked for 8-week timelines on brightening products regularly. For a simple radiance product — optical brighteners, mild AHA, no melanin-suppression actives — 10–12 weeks is achievable. For anything with a real brightening active stack and a multi-market regulatory target, 16–24 weeks is realistic. Here’s why.

Weeks 1–3: brief alignment, market and regulatory scoping, initial formula architecture. This phase takes longer than brands expect because the regulatory questions have to be resolved before we commit to an active selection. We’ve had projects where the brief alignment alone took four weeks because the brand was still deciding between EU-only and EU + China launch. That decision changes the formula.

Weeks 4–8: prototype development, initial stability setup, pH and compatibility screening. We typically run three to five formula variants in parallel at this stage. Accelerated stability starts at week 4 — we need at least 8 weeks of 40°C data before we’re comfortable recommending a formula for scale-up.

Weeks 9–14: stability review, sensory evaluation, packaging compatibility testing. Packaging compatibility is underestimated. We’ve had ascorbyl formulas that were perfectly stable in glass but showed significant degradation in certain HDPE tubes due to oxygen permeability. We now require packaging compatibility testing as a non-negotiable step for any oxidation-sensitive formula.

Weeks 15–20+: scale-up batch, production stability, regulatory documentation. For China registration, add 6–12 months to the timeline after formula lock. That’s not our timeline — that’s the NMPA process. Brands need to plan for it.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask in every brightening kickoff, and the answers shape everything downstream.

If you’re launching EU + US with a “dark spot” or “uneven tone” claim, we can work within a clean, EU-compliant active stack — niacinamide, tranexamic acid, alpha-arbutin, ascorbyl derivatives — and build a formula that’s both effective and straightforward to register. Timeline is 16–20 weeks to production-ready formula. If you want clinical substantiation for claim support, add 12 weeks for a consumer panel or 16 weeks for an instrumental study.

If China is in scope, we need to know that on day one. The NMPA whitening pathway changes the active selection, the study requirements, and the timeline in ways that can’t be retrofitted after formula lock. We’ve had brands come to us at week 12 of development wanting to add China to their launch plan. That conversation is painful. The formula usually needs to be rebuilt.

On concentration: more is not always better, and in some cases it creates problems — stability, regulatory, sensory. We’ll push back if a requested concentration creates a formulation risk. That’s part of what we’re here for. Budget for packaging early. For premium brightening, airless or UV-protective packaging is not optional if you want the stability data to hold.

Frequently Asked Questions #

Q: We want to put “whitening” on the pack for our China launch — is that straightforward?

Not straightforward, no. “Whitening” and “freckle-removing” are special-use cosmetic claims under NMPA, which means a separate registration dossier, approved actives only, and human efficacy data with colorimetric measurement. Budget 6–12 months for registration after formula lock, on top of your development timeline.

Q: Can we use kojic acid in our EU formula?

You can, but with caution. The current SCCS opinion sets a maximum of 1.0% in face products. The regulatory status is still under review, and we’ve seen some EU retailers add kojic acid to their own restricted lists ahead of any formal ban. If EU retail distribution is part of your plan, check with your retail partners before we build the formula around it.

Q: What’s the minimum niacinamide concentration that actually does something?

Clinically, 4% is where the evidence base is solid for hyperpigmentation. Below that, you’re in radiance territory — it may still contribute, but the claim support gets thinner. We don’t formulate below 4% for any product making a brightening efficacy claim.

Q: How long does a brightening serum take to develop if we want EU and China launch?

For formula development alone, 18–24 weeks to a production-ready, stability-confirmed formula. China registration adds 6–12 months on top of that. If you need clinical data for the NMPA dossier, the study needs to start no later than week 8 of development to avoid delaying registration. Total timeline from brief to China shelf: plan for 18–24 months minimum.

Q: We’ve seen competitors using 20% vitamin C — can we match that?

We’d push back on that brief. At 20% L-ascorbic acid, you’re at pH 2.5–3.0, which is aggressive for a leave-on product, creates significant stability challenges, and sits in regulatory grey territory for some EU markets depending on the product format. Our standard for a stable, effective ascorbyl system is 3-O-ethyl ascorbic acid at 1.5–2.0% or ascorbyl glucoside at 2.0–3.0%, both at pH 4.8–5.5. The stability data is better, the sensory is better, and the regulatory exposure is lower. The “20% vitamin C” on a competitor pack often refers to a derivative, not L-ascorbic acid — check the INCI before benchmarking against it.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.